Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

TAKEDA PHARMACEUTICAL CO LTD

(4502)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Takeda Pharmaceutical : Bracing for 383-B.-Yen Net Loss for FY 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 06:40am EDT

Takeda Pharmaceutical Co. said Tuesday that it expects to incur a consolidated net loss of 383 billion yen in fiscal 2019 to next March, compared with the 109,126-million-yen net profit in the previous year.

The bottom line will be dented by 796 billion yen due to an accounting factor related to the Japanese drug maker's 6.2-trillion-yen acquisition of major Irish peer Shire PLC in January. Specifically, Takeda reevaluated inventories at Shire at market value.

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
SHIRE 2.42% 4690 End-of-day quote.0.00%
TAKEDA PHARMACEUTICAL CO LTD -1.41% 3697 End-of-day quote.2.13%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TAKEDA PHARMACEUTICAL CO L
06/11TAKEDA PHARMACEUTICAL : Amyloidosis treatment discontinued from clinical trials
AQ
06/09TAKEDA PHARMACEUTICAL : Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Am..
AQ
06/07TAKEDA PHARMACEUTICAL : ditches late-stage Ninlaro trial
AQ
06/05TAKEDA PHARMACEUTICAL : Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Am..
BU
06/04TAKEDA PHARMACEUTICAL : Presents Results from Lung Portfolio Including Phase 1/2..
AQ
06/04TAKEDA PHARMACEUTICAL : New Ad-hoc Analysis of Phase 3 HELP Study Evaluates Prev..
AQ
06/03TAKEDA PHARMACEUTICAL : Presents Results from Lung Portfolio
PU
06/03TAKEDA PHARMACEUTICAL : Presents Results from Lung Portfolio Including Phase 1/2..
BU
06/03TAKEDA PHARMACEUTICAL : Beghou Consulting hires former Takeda executive to lead ..
AQ
06/03TAKEDA PHARMACEUTICAL : New Ad-hoc Analysis of Phase 3 HELP Study™ Evaluat..
BU
More news
Financials (JPY)
Sales 2020 3 354 B
EBIT 2020 379 B
Net income 2020 -124 780 M
Debt 2020 4 792 B
Yield 2020 4,88%
P/E ratio 2020 -
P/E ratio 2021 31,81
EV / Sales 2020 3,15x
EV / Sales 2021 2,91x
Capitalization 5 775 B
Chart TAKEDA PHARMACEUTICAL CO LTD
Duration : Period :
Takeda Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 5 475  JPY
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Managing Director & Head-Globalization
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD2.13%51 782
JOHNSON & JOHNSON8.55%348 981
PFIZER-2.04%233 072
ROCHE HOLDING LTD.13.39%227 848
NOVARTIS20.35%220 893
MERCK AND COMPANY8.34%206 641